-Reuters
Fate Therapeutics Highlights Abstract On FT538, FT573 Programs Were Selected For Presentation at Society For Immunotherapy Of Cancer Meeting Nov. 10 12:30-2 p.m. EST
Company to Host Virtual Investor Event on Monday, November 15
SAN DIEGO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development